{
    "clinical_study": {
        "@rank": "37017", 
        "brief_summary": {
            "textblock": "To evaluate the safety and immunogenicity of HIV-1 MN rgp160 (Immuno-AG) in HIV-infected\n      patients. To evaluate the immunogenicity of HIV-1 MN rgp160 immunogen by lymphocyte\n      proliferation, specific antibody responses, and DTH reaction.  To describe the durability of\n      the immunogen in patients who respond to the first 7 injections when they are boosted every\n      8 weeks for an additional 6-12 months [AS PER AMENDMENT 11/12/96: stratum 1 patients only].\n      To describe the ability of the immunogen to induce a response after an additional 6-12\n      months of injections among patients who did not respond to the first 7 injections [AS PER\n      AMENDMENT 11/12/96: stratum 1 patients only].\n\n      HIV-specific cellular immune responses appear to play an important role in HIV disease\n      progression since both T helper and cytotoxic function against HIV decrease with disease\n      progression."
        }, 
        "brief_title": "A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells", 
        "completion_date": {
            "#text": "May 1999", 
            "@type": "Actual"
        }, 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "HIV-specific cellular immune responses appear to play an important role in HIV disease\n      progression since both T helper and cytotoxic function against HIV decrease with disease\n      progression.\n\n      Patients with CD4 counts greater than or equal to 500 cells/mm3 are randomized to receive\n      HIV-1 MN rgp160 (Immuno-AG) or control. Patients with CD4 counts 50-499 cells/mm3 receive\n      didanosine (ddI) and are then randomized to receive ddI plus vaccine or control. Vaccine or\n      control is given every 4 weeks for 7 injections, then every 8 weeks for 6-12 months or until\n      1 year after the last patient is randomized. AS PER AMENDMENT 11/12/96: Stratum 1 is\n      composed of 16 subjects with CD4+ T cells greater than or equal to 500 mm3. These subjects\n      are randomized to vaccine therapy or vaccine control. HIV-1 MN rgp160 vaccine or control is\n      given every 4 weeks for 7 injections (Schedule 1), then every 8 weeks until 52 weeks after\n      the last subject has been randomized to stratum 1 (Schedule 2). Stratum 1 patients receive\n      ddI or d4T only if their CD4 cell count has a sustained decrease on 2 consecutive occasions\n      10-14 days apart and/or HIV/RNA plasma viral load increases to greater than 10,000 copies/ml\n      on 2 consecutive occasions 10-14 days apart. Stratum 2 is composed of 30 subjects with CD4+\n      T cells 200-400/mm3; accrual to this stratum was activated based on preliminary results from\n      stratum 1 (closed as of 4/5/97).  Patients on stratum 2 (open as of 3/4/97) initially\n      receive ritonavir at escalating doses for 2 weeks. Subjects then have ddI and d4T added to\n      the regimen for 7 weeks. Subjects are then randomized to vaccine therapy or vaccine control\n      every 4 weeks for 7 injections, with ritonavir/ddI/d4T continued during vaccine therapy.\n\n      AS PER AMENDMENT 3/23/98: As of 6/1/98 vaccine consists of sodium chloride for injection\n      (USP)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  ddI [AS PER AMENDMENT 11/12/96: and d4T]. (Note:\n\n          -  Patients in the stratum receiving only vaccine or control may take ddI [AS PER\n             AMENDMENT 11/12/96:\n\n          -  and d4T] ONLY IF their CD4 counts have shown a sustained decrease on two consecutive\n             occasions 10-14 days apart.)\n\n          -  PCP prophylaxis.\n\n          -  Treatment for acute conditions, as indicated.\n\n        AS PER AMENDMENT 11/12/96:\n\n          -  Co-enrollment on other research trials.\n\n        Patients must have:\n\n          -  HIV positivity.\n\n          -  Asymptomatic disease.\n\n          -  CD4 count >= 50 cells/mm3 (CD4 count must be 50-499 cells/mm3 in patients receiving\n             ddI plus vaccine or control, and must be >= 500 cells/mm3 in patients receiving\n             vaccine or control only)\n\n        [AS PER AMENDMENT 11/12/96:\n\n          -  CD4 count >= 500 cells/mm3 for stratum 1 patients and 200-400 for stratum 2\n             patients].\n\n          -  HLA A2 positive documentation.\n\n          -  An Epstein Barr virus B cell line established within 90 days prior to study entry.\n\n          -  Consent of parent or guardian if less than 18 years of age.\n\n        NOTE:\n\n          -  Study is NOT approved for prisoner participation.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Medical contraindication to study participation or inability to comply with study\n             requirements.\n\n          -  Grade 2 or worse peripheral neuropathy (applicable only to patients receiving ddI\n             plus vaccine or control).\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Immunomodulating agents, such as inosiplex, ditiocarb sodium, lithium, interferons,\n             interleukin-2, and systemic steroids.\n\n          -  Any antiretroviral therapy that may increase the risk of peripheral neuropathy (e.g.,\n             stavudine, zalcitabine [AS PER AMENDMENT 11/12/96:\n\n          -  e.g., zalcitabine or lamivudine]).\n\n          -  Agents such as IV pentamidine that may increase the risk of pancreatitis.\n\n          -  Standard of care vaccines (in patients receiving vaccine) [AS PER AMENDMENT 11/12/96:\n\n          -  Standard of care immunizations are permitted 60 days before Schedule 1 vaccine\n             therapy and during Schedule 2 vaccine therapy (but not within 2 weeks of study\n             immunization)].\n\n        AS PER AMENDMENT 11/12/96:\n\n          -  Rifabutin, disulfiram (antabuse), or other medication with similar effects, including\n             metronidazole.\n\n             6.AS PER AMENDMENT 11/12/96:\n\n          -  The following are prohibited in patients receiving ritonavir:\n\n          -  amiodarone, astemizole, bepridil, bupropion, cisapride, clozapine, encainide,\n             flecainide, meperidine, piroxicam, propafenone, propoxyphene, quinidine, rifabutin,\n             terfenadine, alprazolam, clorazepate, diazepam, estazolam, flurazepam, midazolam,\n             triazolam, and zolpidem.\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of grade 2 or worse liver abnormality.\n\n          -  Known allergy to vaccine components.\n\n          -  Chronic diarrhea persisting for 4 or more weeks within 30 days prior to study entry.\n\n          -  History of pancreatitis (applicable only to patients receiving ddI plus vaccine or\n             control). [AS PER AMENDMENT 11/12/96:\n\n          -  History of chronic pancreatitis or history of acute pancreatitis within 2 years prior\n             to entry (stratum 2 patients only).]\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Any prior anti-HIV vaccines.\n\n        Excluded within 90 days prior to study entry:\n\n          -  Immunomodulating agents, such as Inosiplex, ditiocarb sodium, lithium, interferons,\n             interleukin-2, and systemic steroids.\n\n          -  Any antiretroviral therapy that may increase the risk of peripheral neuropathy (e.g.,\n             stavudine, zalcitabine [AS PER AMENDMENT 11/12/96:\n\n          -  e.g., zalcitabine or lamivudine]).\n\n          -  Agents such as IV pentamidine that may increase the risk of pancreatitis.\n\n          -  Any treatment for an AIDS-defining illness (applicable ONLY to patients in the\n             stratum receiving ddI plus vaccine or control).\n\n        Excluded within 6 months prior to study entry:\n\n          -  Any other antiretrovirals or immunomodulators besides those mentioned above.\n\n          -  Allergy desensitization or other vaccines [AS\n\n        PER AMENDMENT 11/12/96:\n\n          -  excluded within 60 days prior to entry]."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "46", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000822", 
            "org_study_id": "ACTG 246/946", 
            "secondary_id": [
                "11223", 
                "11499"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "Ritonavir", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "gp160 Vaccine (Immuno-AG)", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "Stavudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Didanosine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Didanosine", 
                "Stavudine", 
                "Reverse Transcriptase Inhibitors", 
                "Ritonavir", 
                "HIV Protease Inhibitors"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Vaccines, Synthetic", 
            "Didanosine", 
            "Drug Therapy, Combination", 
            "HIV Envelope Protein gp160", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Stavudine", 
            "HIV Protease Inhibitors", 
            "AIDS Vaccines", 
            "Ritonavir", 
            "Reverse Transcriptase Inhibitors", 
            "HIV Therapeutic Vaccine"
        ], 
        "lastchanged_date": "May 8, 2012", 
        "link": [
            {
                "description": "Click here for more information about Didanosine", 
                "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=16"
            }, 
            {
                "description": "Click here for more information about Stavudine", 
                "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=43"
            }, 
            {
                "description": "Click here for more information about Ritonavir", 
                "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=244"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "943055107"
                }, 
                "name": "Stanford CRS"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells", 
        "overall_official": [
            {
                "last_name": "Kundu Smriti", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Merigan T", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": [
            {
                "citation": "Katzenstein D, Valentine F, Kundu S, Haslett P, Smith G, Merigan T. Delayed-type-hypersensitivity reactions to intradermal gp160 in HIV infected individuals immunized with gp160. Int Conf AIDS. 1992 Jul 19-24;8(2):A35 (abstract no PoA 2192)"
            }, 
            {
                "PMID": "11679149", 
                "citation": "Kundu-Raychaudhuri S, Sevin A, Kilgo P, Nokta M, Pollard RB, Merigan TC. Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946). AIDS Res Hum Retroviruses. 2001 Oct 10;17(15):1371-8."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000822"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Bristol-Myers Squibb", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Immuno-US", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2012"
    }, 
    "geocoordinates": {
        "Stanford CRS": "37.429 -122.169"
    }
}